Washington: Researchers have found that cancers physically alter cells in the lymphatic system - a network of vessels that transports and stores immune cells throughout the body - to promote the spread of disease, a process called metastasis.
Roughly 90 percent of all cancer deaths are due to metastasis - the disease spreading from the original tumour site to multiple, distant tissues and finally overwhelming the patient`s body.
Lymph vessels are often the path of transmission, with circulating tumour cells lodging in the lymph nodes - organs distributed throughout the body that act as immune system garrisons and traps for pathogens and foreign particles.
Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center found that a protein growth factor expressed by tumours called VEGF-C activates a receptor called integrin a4beta1 on lymphatic vessels in lymph node tissues, making them more attractive and sticky to metastatic tumour cells.
"One of the most significant features of this work is that it highlights the way that tumours can have long-range effects on other parts of the body, which can then impact tumour metastasis or growth," said principal investigator Judith A. Varner, PhD, professor of medicine at UC San Diego Moores Cancer Center.
Varner said a4beta1 could prove to be a valuable biomarker for measuring cancer risk, since increased levels of the activated protein in lymph tissues is an indirect indicator that an undetected tumour may be nearby.
She said whole-body imaging scans of the lymphatic network might identify problem areas relatively quickly and effectively.
"The idea is that a radio-labeled or otherwise labeled anti-integrin a4beta1 antibody could be injected into the lymphatic circulation, and it would only bind to and highlight the lymphatic vessels that have been activated by the presence of a tumour," she explained.
Varner noted that a4beta1 levels correlate with metastasis - the higher the level, the greater the chance of the cancer spreading. With additional research and clinical studies, doctors could refine treatment protocols so that patients at higher risk are treated appropriately, but patients at lower or no risk of metastasis are not over-treated.
The researchers noted in their studies that it is possible to suppress tumour metastasis by reducing growth factor levels or by blocking activation of the a4beta1 receptor.
Varner said an antibody to VEGF-R3 is currently in Phase 1 clinical trials. An approved humanized anti-a4beta1 antibody is currently approved for the treatment of multiple sclerosis and Crohn`s disease.
Varner said her lab at UC San Diego Moores Cancer Center is investigating the possibility of developing one for treating cancer.
The findings are published in this week`s online Early Edition of the Proceedings of the National Academy of Sciences.
ANI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.